| Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs MGG Sturkenboom, AG Märtson, EM Svensson, DJ Sloan, KE Dooley, ... Clinical pharmacokinetics 60, 685-710, 2021 | 62 | 2021 |
| Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring SHJ van den Elsen, LM Oostenbrink, SK Heysell, D Hira, DJ Touw, ... Therapeutic drug monitoring 40 (1), 17-37, 2018 | 50 | 2018 |
| Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients SHJ van den Elsen, MGG Sturkenboom, N Van't Boveneind-Vrubleuskaya, ... Antimicrobial agents and chemotherapy 62 (12), e01092-18, 2018 | 39 | 2018 |
| Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients SHJ van den Elsen, MGG Sturkenboom, OW Akkerman, K Manika, ... Antimicrobial Agents and Chemotherapy 63 (7), e00384-19, 2019 | 27 | 2019 |
| Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs J Kuhlin, MGG Sturkenboom, S Ghimire, I Margineanu, ... Clinical Mass Spectrometry 14, 34-45, 2019 | 22 | 2019 |
| Membrane filtration is suitable for reliable elimination of Mycobacterium tuberculosis from saliva for therapeutic drug monitoring SHJ van den Elsen, T van der Laan, OW Akkerman, AGM van der Zanden, ... Journal of Clinical Microbiology 55 (11), 3292-3293, 2017 | 19 | 2017 |
| Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin SHJ van den Elsen, OW Akkerman, EM Jongedijk, M Wessels, S Ghimire, ... European Respiratory Journal 55 (5), 2020 | 18 | 2020 |
| Lack of penetration of amikacin into saliva of tuberculosis patients SHJ van den Elsen, OW Akkerman, JR Huisman, DJ Touw, ... European Respiratory Journal 51 (1), 1702024, 2018 | 16 | 2018 |
| Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid SHJ van den Elsen, OW Akkerman, M Wessels, EM Jongedijk, S Ghimire, ... European Respiratory Journal 56 (4), 2020 | 12 | 2020 |
| Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a … SHJ van den Elsen, MGG Sturkenboom, O Akkerman, L Barkane, ... BMJ open 10 (6), e035350, 2020 | 6 | 2020 |
| Cross-validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Quantification of Levofloxacin in Saliva S Ghimire, EM Jongedijk, SHJ van den Elsen, MA Wessels, DJ Touw, ... Journal of Applied Bioanalysis 6 (2), 68-70, 2020 | 5 | 2020 |
| Corrigendum to “Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs”[Clin. Mass Spectrom. 14 (Part A)(2019) 34–45] J Kuhlin, MGG Sturkenboom, S Ghimire, I Margineanu, ... Journal of Mass Spectrometry and Advances in the Clinical lab 25, 72, 2022 | 1 | 2022 |
| Antitubercular Agents SHJ van den Elsen, OW Akkerman, M Wessels, EM Jongedijk, S Ghimire, ... | | 2020 |
| Therapeutic Drug Monitoring in Tuberculosis Treatment: the Use of Alternative Matrices and Sampling Strategies S van den Elsen Rijksuniversiteit Groningen, 2020 | | 2020 |
| Potentials for salivary therapeutic drug monitoring of anti-tuberculosis drugs S van den Elsen | | 2018 |
